Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulator Addition for Anti-TNF Loss of Response in IBD
NCT02413047Terminated
- Sponsor
- Indiana University
- Start
- May 2015
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of azathioprine, mercaptopurine and methotrexate in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC), sponsored by Indiana University. Primary endpoints: Harvey Bradshaw Index at 4 months, Therapeutic Trough Level for Infliximab at 4 months and 5 more. Started May 2015; status: terminated.
02
Drugs
azathioprinemercaptopurinemethotrexate
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02413047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413047.